Argenx Se ADR (ARGX)

Apr 4, 2025, 2:30 PM EDT - 3 hours ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI CCL CEPU CF CROX CUK DECK

Mar 7, 2025, 1:00 AM EST - 4 weeks ago

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Feb 27, 2025, 3:17 PM EST - 5 weeks ago

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:58 AM EST - 5 weeks ago

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27, 2025, 1:00 AM EST - 5 weeks ago

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Feb 25, 2025, 1:00 AM EST - 5 weeks ago

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 1:00 AM EST - 6 weeks ago

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Jan 13, 2025, 1:00 AM EST - 2 months ago

argenx Highlights 2025 Strategic Priorities

Jan 6, 2025, 1:00 AM EST - 3 months ago

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 1:00 AM EST - 3 months ago

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Nov 26, 2024, 1:00 AM EST - 4 months ago

argenx to Present at Upcoming Investor Conferences

Nov 20, 2024, 1:00 AM EST - 4 months ago

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Nov 19, 2024, 9:10 AM EST - 4 months ago

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

Nov 11, 2024, 7:30 AM EST - 5 months ago

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Nov 11, 2024, 7:30 AM EST - 5 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ZLAB

Nov 5, 2024, 1:00 AM EST - 5 months ago

argenx to Participate at Upcoming Investor Conferences

Oct 31, 2024, 1:29 PM EDT - 5 months ago

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31, 2024, 1:08 PM EDT - 5 months ago

argenx SE (ARGX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:00 AM EDT - 5 months ago

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 24, 2024, 1:00 AM EDT - 5 months ago

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Oct 15, 2024, 1:00 AM EDT - 6 months ago

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Sep 24, 2024, 9:06 PM EDT - 6 months ago

argenx: Myositis Data Could Add Billions In Value

Sep 19, 2024, 1:00 AM EDT - 7 months ago

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Aug 12, 2024, 5:13 PM EDT - 8 months ago

Biotech stocks: Which drugmakers are worth a buy?

NVCR

Jul 25, 2024, 1:00 AM EDT - 9 months ago

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

Jul 18, 2024, 1:00 AM EDT - 9 months ago

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

Jul 16, 2024, 12:30 AM EDT - 9 months ago

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Jul 16, 2024, 12:15 AM EDT - 9 months ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

ZLAB

Jun 28, 2024, 10:20 AM EDT - 10 months ago

Argenx: Strong Setup For Outperformance In 2025

Jun 25, 2024, 4:30 PM EDT - 10 months ago

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Jun 24, 2024, 12:43 PM EDT - 10 months ago

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Jun 21, 2024, 4:50 PM EDT - 10 months ago

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 17, 2024, 1:00 AM EDT - 10 months ago

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024

Jun 4, 2024, 1:00 AM EDT - 10 months ago

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 9, 2024, 4:39 PM EDT - 11 months ago

argenx SE (ARGX) Q1 2024 Earnings Call Transcript

May 9, 2024, 1:00 AM EDT - 11 months ago

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 5:30 PM EDT - 11 months ago

argenx announces results of Annual General Meeting of Shareholders

May 7, 2024, 4:02 AM EDT - 11 months ago

argenx: Innovation Over Losses In Autoimmune Arena

May 7, 2024, 1:00 AM EDT - 11 months ago

argenx to Present at BofA Securities 2024 Health Care Conference

May 2, 2024, 1:00 AM EDT - 1 year ago

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

Apr 16, 2024, 1:00 AM EDT - 1 year ago

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Mar 27, 2024, 2:00 AM EDT - 1 year ago

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Mar 26, 2024, 4:00 PM EDT - 1 year ago

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

Mar 26, 2024, 2:00 AM EDT - 1 year ago

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Mar 7, 2024, 4:01 PM EST - 1 year ago

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Feb 29, 2024, 1:26 PM EST - 1 year ago

argenx SE (ARGX) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:00 AM EST - 1 year ago

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Feb 22, 2024, 1:00 AM EST - 1 year ago

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

Feb 20, 2024, 1:00 AM EST - 1 year ago

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Feb 1, 2024, 7:22 AM EST - 1 year ago

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion